RCT | Ozoralizumab vs. placebo in patients with active rheumatoid arthritis despite methotrexate therapy.

Phase II/III results of the anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’ in patient with rheumatoid arthritis (OHZORA trial) – Arthritis & Rheumatology

Commentary: Ozoralizumab shows promise in methotrexate-resistant RA – medwire News